Ciccia, Francesco <br/><br/>
Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.  [electronic resource] 

 -  Rheumatology (Oxford, England)  Jul 2014 
 - 1313-20 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1462-0332 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/keu004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Murine-Derived--pharmacology<br/>Antirheumatic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Female<br/>Humans<br/>In Vitro Techniques<br/>Interferons<br/>Interleukin-17--metabolism<br/>Interleukin-23--metabolism<br/>Interleukins--metabolism<br/>Male<br/>Mast Cells--drug effects<br/>Middle Aged<br/>Rituximab<br/>STAT3 Transcription Factor<br/>Salivary Glands--drug effects<br/>Signal Transduction--drug effects<br/>Sjogren's Syndrome--drug therapy<br/>Th17 Cells--drug effects<br/>Treatment Outcome